A Mouse Mammary Gland Involution mRNA Signature Identifies Biological Pathways Potentially Associated with Breast Cancer Metastasis

Torsten Stein · Nathan Salomonis ·
Dimitry S. A. Nuyten · Marc J. van de Vijver ·
Barry A. Gusterson

Published online: 28 May 2009
© Springer Science + Business Media, LLC 2009

Erratum to: J Mammary Gland Biol Neoplasia DOI 10.1007/s10911-009-9120-1

The original version of this article unfortunately contained a mistake. The presentation of Tables 1 and 2 were incorrect. The corrected tables are given below.

The Publishers apologise for the errors that exist in the tables in this article. The errors were introduced by the publisher during the publication process at a stage that was too late to be corrected.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10911-009-9120-1>.

T. Stein · B. A. Gusterson
Division of Cancer Sciences and Molecular Pathology,
Section of Gene Regulation and Mechanisms of Disease,
Western Infirmary, University of Glasgow,
Glasgow G11 6NT, UK

N. Salomonis
Gladstone Institute of Cardiovascular Disease,
1650 Owens Street,
San Francisco, CA 94158, USA

N. Salomonis
Pharmaceutical Sciences and Pharmacogenomics Graduate
Program, University of California,
513 Parnassus Avenue,
San Francisco, CA 94143, USA

D. S. A. Nuyten
Department of Radiation Oncology,
The Netherlands Cancer Institute,
Plesmanlaan 121,
Amsterdam 1066 CX, The Netherlands

D. S. A. Nuyten
Division of Diagnostic Oncology,
The Netherlands Cancer Institute,
Plesmanlaan 121,
Amsterdam 1066 CX, The Netherlands

D. S. A. Nuyten · M. J. van de Vijver
Division of Experimental Therapy, The Netherlands Cancer
Institute, Antoni van Leeuwenhoek Hospital,
Plesmanlaan 121,
Amsterdam 1066 CX, The Netherlands

M. J. van de Vijver
Department of Pathology, Academic Medical Center,
Meibergdreef 9,
Amsterdam 1105 AZ, The Netherlands

T. Stein (✉)
Division of Cancer Sciences and Molecular Pathology,
Section of Pathology and Gene Regulation, Western Infirmary,
University of Glasgow,
Glasgow G11 6NT, UK
e-mail: T.Stein@clinmed.gla.ac.uk

Table 1 Cox regression tables for involution signatures (Survival).

Variable	Significance	Hazard Ratio for Death	95.0% CI for HR	
			Lower	Upper
A: Clinical risk factors and Inv3 signature: survival (Cox regression)				
Diameter T2 (>2cm) vs T1 (≤2cm)	0.07	1.48	0.98	2.26
Lymph node positive vs negative	0.34	1.35	0.73	2.51
Age above 40 versus 40 and below	0.14	0.71	0.45	1.11
ER positive vs negative	0.15	0.71	0.45	1.13
Grade 3 vs 2 vs 1	0.01	1.61	1.15	2.24
Chemotherapy, yes vs no	0.48	0.80	0.43	1.48
Hormonal therapy, yes vs no	0.43	0.74	0.35	1.56
Inv3 Signature, poor vs good	0.003	2.36	1.33	4.17
B: Clinical risk factors and C5 signature: survival (Cox regression)				
Diameter T2 (>2cm) vs T1 (≤2cm)	0.07	1.48	0.98	2.26
Lymph node positive vs negative	0.19	1.52	0.81	2.85
Age above 40 versus 40 and below	0.08	0.67	0.43	1.05
ER positive vs negative	0.38	0.82	0.51	1.29
Grade 3 vs 2 vs 1	0.01	1.59	1.14	2.22
Chemotherapy, yes vs no	0.25	0.69	0.37	1.30
Hormonal therapy, yes vs no	0.44	0.75	0.35	1.57
C5 Signature, poor vs good	<10 ⁻³	2.94	1.66	5.20
C: Clinical risk factors and Inv3/C5 signature: survival (Cox regression)				
Diameter T2 (>2cm) vs T1 (≤2cm)	0.12	1.39	0.91	2.12
Lymph node positive vs negative	0.22	1.49	0.79	2.84
Age above 40 versus 40 and below	0.07	0.66	0.42	1.04
ER positive vs negative	0.19	0.74	0.47	1.16
Grade 3 vs 2 vs 1	0.001	1.72	1.24	2.37
Chemotherapy, yes vs no	0.39	0.76	0.40	1.43
Hormonal therapy, yes vs no	0.43	0.74	0.35	1.56
Inv3/C5 Signature, poor vs good	<10 ⁻³	3.13	1.69	5.80

Table 2 Cox regression tables for involution signatures (Metastasis).

Variable	Significance	Hazard Ratio for Metastasis	95.0% CI for HR	
			Lower	Upper
A: Clinical risk factors and Inv3 signature: metastasis (Cox regression)				
Diameter T2 (>2cm) vs T1 (≤2cm)	0.02	1.62	1.10	2.39
Lymph node positive vs negative	0.17	1.49	0.84	2.62
Age above 40 versus 40 and below	0.06	0.67	0.44	1.02
ER positive vs negative	0.53	1.16	0.73	1.84
Grade 3 vs 2 vs 1	0.04	1.36	1.02	1.81
Chemotherapy, yes vs no	0.22	0.70	0.40	1.23
Hormonal therapy, yes vs no	0.19	0.64	0.33	1.25
Inv3 Signature, poor vs good	<10 ⁻³	2.77	1.66	4.64
B: Clinical risk factors and C5 signature: metastasis (Cox regression)				
Diameter T2 (>2cm) vs T1 (≤2cm)	0.01	1.63	1.11	2.41
Lymph node positive vs negative	0.06	1.74	0.98	3.09
Age above 40 versus 40 and below	0.02	0.62	0.41	0.94
ER positive vs negative	0.29	1.29	0.81	2.05
Grade 3 vs 2 vs 1	0.03	1.39	1.04	1.85
Chemotherapy, yes vs no	0.08	0.60	0.34	1.07
Hormonal therapy, yes vs no	0.19	0.64	0.33	1.26
C5 Signature, poor vs good	<10 ⁻⁴	2.80	1.71	4.58
C: Clinical risk factors and Inv3/C5 signature: metastasis (Cox regression)				
Diameter T2 (>2cm) vs T1 (≤2cm)	0.03	1.54	1.04	2.27
Lymph node positive vs negative	0.08	1.67	0.93	2.98
Age above 40 versus 40 and below	0.03	0.63	0.42	0.95
ER positive vs negative	0.57	1.14	0.72	1.80
Grade 3 vs 2 vs 1	0.004	1.51	1.14	2.00
Chemotherapy, yes vs no	0.19	0.68	0.38	1.20
Hormonal therapy, yes vs no	0.22	0.66	0.33	1.29
Inv3/C5 Signature, poor vs good	<10 ⁻³	2.48	1.50	4.11